

NOV 29 2006

Docket No. 295086US0PCT

MAIL STOP PCT *IFW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kouichi TAMURA, et al.

SERIAL NO: 10/591,287

GAU:

FILED: August 31, 2006

EXAMINER:

FOR: ANTI FK778ANTIBODIES AND HIGH SENSITIVE IMMUNOASSAY METHODS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Surinder Sachar

Norman F. Oblon
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar
Registration No. 34,423



SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 295086US0PCT	SHEET 1 OF 1 NOV 29 2006 PATENT & TRADEMARK OFFICE JAPAN		
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Kouichi TAMURA, et al.					
		FILING DATE August 31, 2006		GROUP 1641			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
/JLG/	AO	03/086391	10/23/03	WO	YES		NO
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
/JLG/	AW	BIRSAN, T. et al., "In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates", Transplant International, Vol. 16, No. 5, Pages 354-360, 2003.					
/JLG/	AX	JOHNSTON, Atholl et al., "Immunosuppressant drugs- the role of therapeutic drug monitoring", British Journal of Clinical Pharmacology, Vol. 52, No. Suppl. 1, Pages 61S-73S, 2001.					
/JLG/	AY	ALAK, Ala M., "Measurement of Tacrolimus (FK506) and Its Metabolites: A Review of Assay Development and Application in Therapeutic Drug Monitoring and Pharmacokinetic Studies", Therapeutic Drug Monitoring, Vol. 19, No.3, Pages 338- 351, 1997.					
/JLG/	AZ	DETERS, Michael et al., " Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants", Analytica Chimica Acta, Vol. 492, No. 1-2, Pages 133-145, 2003.					
Examiner	/James L. Grun/					<input type="checkbox"/> Additional References sheet(s) attached <input type="checkbox"/> Date Considered 06/18/2008	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. PCT Application Serial No: 10/591,287

Filed: August 31, 2006

Kouichi TAMURA, et al.

Docket No. 295086 US

STATEMENT OF RELEVANCY

- 1) References AW - AZ have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) Reference AO is discussed in the specification. A copy of this reference is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.